Investigational Drug Developed by UAB and NIH Researchers Being Used to Treat Coronavirus

By Savannah Koplon

The investigational drug remdesivir, developed through research conducted through the Antiviral Drug Discovery and Development Center, or AD3C, and centered at the University of Alabama at Birmingham, is being used to treat select patients in the United States and in China who have been infected by the novel coronavirus (2019-nCoV).

UAB was awarded a $37.5 million, five-year U19 grant from the National Institute of Allergy and Infectious Diseases Centers of Excellence for Translational Research to study and develop treatment for high-priority emerging infections. Work has been taking place to develop drugs for emerging influenza, flaviviruses (dengue, West Nile virus and Zika), coronaviruses that cause SARS and MERS, and alphaviruses such as Venezuelan equine encephalitis virus and chikungunya. The grant is a multi-institutional collaboration to accelerate drug discovery for these emerging infections and is a public-private partnership between academic institutions and Gilead Sciences.

Please CLICK HERE to read the complete article on the Alabama NewsCenter website.

Category: ALL POSTS, Partner News Stories